Campath® and Rituxan® Promising for Untreated High-risk CLL
October 7, 2008 — Researchers from the Mayo Clinic have reported that early treatment of asymptomatic patients with high-risk features of chronic lymphocytic leukemia (CLL) with Campath® (alemtuzumab) and Rituxan® (rituximab) appears promising. The details of this study appeared in the October 15, 2008 issue of Cancer.
Long-term Incense Use Increases Risk of Cancer Upper Respiratory Tract Cancer
October 7, 2008 — Researchers from Singapore have reported that long-term incense use increases the risk of squamous cell carcinoma of the respiratory tract. The details of this study appeared in the October 1, 2008 issue of Cancer.
Arimidex® Not Associated with Cognitive Impairment Among Postmenopausal Women at High Risk for Breast Cancer
October 7, 2008 — The use of the aromatase inhibitor Arimidex® (anastrozole) does not appear to be associated with cognitive impairment among postmenopausal women at a high risk of developing breast cancer. These results were recently published in the Lancet Oncology.
Select news items provided by Reuters Health